Preprint Review Version 2 Preserved in Portico This version is not peer-reviewed

2-Deoxy-d-glucose Inhibits Replication of Novel Coronavirus (SARS-CoV-2) with Adverse Effects on Host Cell Metabolism

Version 1 : Received: 10 June 2021 / Approved: 14 June 2021 / Online: 14 June 2021 (08:44:50 CEST)
Version 2 : Received: 22 June 2021 / Approved: 1 July 2021 / Online: 1 July 2021 (13:04:43 CEST)

How to cite: Malgotra, V.; Sharma, V. 2-Deoxy-d-glucose Inhibits Replication of Novel Coronavirus (SARS-CoV-2) with Adverse Effects on Host Cell Metabolism. Preprints 2021, 2021060333 (doi: 10.20944/preprints202106.0333.v2). Malgotra, V.; Sharma, V. 2-Deoxy-d-glucose Inhibits Replication of Novel Coronavirus (SARS-CoV-2) with Adverse Effects on Host Cell Metabolism. Preprints 2021, 2021060333 (doi: 10.20944/preprints202106.0333.v2).

Abstract

The treatment of viral infections is challenging owing to the intricate structure and metabolism of the viruses. In addition, they can highjack host cellular metabolism, mutate and adapt to harsh environmental conditions. The novel coronavirus (SARS-CoV-2) displays further resilient attributes, making its eradication even more difficult. SARS-CoV-2 is an enveloped virus whose replication can be targeted by limiting the substrates available for structural incorporation. One such molecule that limits substrate availability and has received much attention lately is 2-Deoxy-d-glucose (2-DG). SARS-CoV-2 infection induces glycolysis, impairs mitochondrial function, and damages the infected cells. Administration of 2-DG can inhibit increased glycolytic flux and some other metabolic processes to cause the cessation of viral replication. This article provides a review of the mechanism of action and safety concerns associated with administering 2-DG in the treatment of COVID-19. The drug can have adverse effects on normal cell metabolism since it targets cells non-selectively, possibly in a dose-dependent manner. In addition, the drug has limited use in SARS-CoV-2 infection associated with stroke, hypoxic-ischemic encephalopathy, and critical illness.

Subject Areas

2-Deoxyglucose; Adverse effects; COVID-19; Glutamine; PI3K/Akt

Comments (1)

Comment 1
Received: 1 July 2021
Commenter: Vikas Malgotra
Commenter's Conflict of Interests: Author
Comment: 1. Changed keywords
2. Changed the figure submitted with the abstract
3. Added a new paragraph: 2-Deoxy-d-glucose may be less effective in the presence of hypoxia and glutamine
4. Added a new line and corrected grammar in "conclusion"
+ Respond to this comment

We encourage comments and feedback from a broad range of readers. See criteria for comments and our diversity statement.

Leave a public comment
Send a private comment to the author(s)
Views 0
Downloads 0
Comments 1
Metrics 0


×
Alerts
Notify me about updates to this article or when a peer-reviewed version is published.
We use cookies on our website to ensure you get the best experience.
Read more about our cookies here.